Jing Sun1, Hongjun Sun2, Meiyu Cui3, Zhijian Sun4, Wenyue Li1, Jianxin Wei1, Shuhua Zhou5. 1. Department of Nephrology, Dezhou People's Hospital, No. 1751, Xinhu Road, Dezhou, 253014, Shandong, People's Republic of China. 2. Department of Blood Transfusion, Dezhou People's Hospital, Dezhou, 253014, Shandong, People's Republic of China. 3. Department of Nephrology, Qianfoshan Hospital, Jinan, 250014, Shandong, People's Republic of China. 4. Department of General Surgery, Dezhou People's Hospital, Dezhou, 253014, Shandong, People's Republic of China. 5. Department of Nephrology, Dezhou People's Hospital, No. 1751, Xinhu Road, Dezhou, 253014, Shandong, People's Republic of China. dzsrmyyzsh@sina.com.
Abstract
PURPOSE: We conducted a meta-analysis to explore the association between the use of different anti-ulcer agents and the risk of chronic kidney disease (CKD), end-stage renal disease (ESRD), and decline in glomerular filtration rate (GFR) in various study populations. METHODS: PubMed, Embase, and the Cochrane Library were searched for relevant entries up to July 1, 2017. The primary outcomes of the meta-analysis were risk ratios (RRs) of CKD, ESRD, and decline in GFR. We also investigated the heterogeneity of the meta-analysis by subgroup analysis and meta-regression analysis. RESULTS: A total of 662,624 individuals were enrolled in five trials. Compared with non-PPI users, PPI users had a higher trend of CKD (RR = 1.16, 95% CI 1.07-1.25, P < 0.001), especially ESRD (RR = 1.81, 95% CI 1.59-2.06, P < 0.001). There was an elevated risk of adverse renal outcome among participants receiving PPI and not H2RA (CKD: RR = 1.28, 95% CI 1.24-1.33, P < 0.001; ESRD: RR = 1.39, 95% CI 1.17-1.64, P < 0.001; GFR: RR = 1.31, 95% CI 1.26-1.36, P < 0.001). However, H2RA users were not associated with CKD when compared with non-H2RA users (RR = 1.02, 95% CI 0.83-1.25, P = 0.855). In subgroup analysis, the average age of individuals and drug dosage had no influence on the risk of CKD, while duration of PPI exposure from 31 to 720 days is a potential factor in progression to ESRD (P < 0.001). CONCLUSIONS: Chronic PPI use, but not H2RAs, is associated with deterioration in kidney function.
PURPOSE: We conducted a meta-analysis to explore the association between the use of different anti-ulcer agents and the risk of chronic kidney disease (CKD), end-stage renal disease (ESRD), and decline in glomerular filtration rate (GFR) in various study populations. METHODS: PubMed, Embase, and the Cochrane Library were searched for relevant entries up to July 1, 2017. The primary outcomes of the meta-analysis were risk ratios (RRs) of CKD, ESRD, and decline in GFR. We also investigated the heterogeneity of the meta-analysis by subgroup analysis and meta-regression analysis. RESULTS: A total of 662,624 individuals were enrolled in five trials. Compared with non-PPI users, PPI users had a higher trend of CKD (RR = 1.16, 95% CI 1.07-1.25, P < 0.001), especially ESRD (RR = 1.81, 95% CI 1.59-2.06, P < 0.001). There was an elevated risk of adverse renal outcome among participants receiving PPI and not H2RA (CKD: RR = 1.28, 95% CI 1.24-1.33, P < 0.001; ESRD: RR = 1.39, 95% CI 1.17-1.64, P < 0.001; GFR: RR = 1.31, 95% CI 1.26-1.36, P < 0.001). However, H2RA users were not associated with CKD when compared with non-H2RA users (RR = 1.02, 95% CI 0.83-1.25, P = 0.855). In subgroup analysis, the average age of individuals and drug dosage had no influence on the risk of CKD, while duration of PPI exposure from 31 to 720 days is a potential factor in progression to ESRD (P < 0.001). CONCLUSIONS: Chronic PPI use, but not H2RAs, is associated with deterioration in kidney function.
Entities:
Keywords:
Anti-ulcer agents; Chronic kidney disease; H2RA; Meta-analysis; PPI
Authors: Derk C F Klatte; Alessandro Gasparini; Hong Xu; Pietro de Deco; Marco Trevisan; Anna L V Johansson; Björn Wettermark; Johan Ärnlöv; Cynthia J Janmaat; Bengt Lindholm; Friedo W Dekker; Josef Coresh; Morgan E Grams; Juan J Carrero Journal: Gastroenterology Date: 2017-06-02 Impact factor: 22.682
Authors: Waleed Alhazzani; Gordon Guyatt; Mohammed Alshahrani; Adam M Deane; John C Marshall; Richard Hall; John Muscedere; Shane W English; François Lauzier; Lehana Thabane; Yaseen M Arabi; Tim Karachi; Bram Rochwerg; Simon Finfer; Nick Daneman; Fayez Alshamsi; Nicole Zytaruk; Diane Heel-Ansdell; Deborah Cook Journal: Crit Care Med Date: 2017-07 Impact factor: 7.598
Authors: Karim El-Kersh; Bilal Jalil; Stephen A McClave; Rodrigo Cavallazzi; Juan Guardiola; Karen Guilkey; Annuradha K Persaud; Stephen P Furmanek; Brian E Guinn; Timothy L Wiemken; Bashar Chihada Alhariri; Scott P Kellie; Mohamed Saad Journal: J Crit Care Date: 2017-08-26 Impact factor: 3.425
Authors: Tony Antoniou; Erin M Macdonald; Simon Hollands; Tara Gomes; Muhammad M Mamdani; Amit X Garg; J Michael Paterson; David N Juurlink Journal: CMAJ Open Date: 2015-04-02
Authors: Charles E Leonard; Cristin P Freeman; Craig W Newcomb; Peter P Reese; Maximilian Herlim; Warren B Bilker; Sean Hennessy; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2012-08-09 Impact factor: 2.890
Authors: Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler Journal: Am J Gastroenterol Date: 2022-01-01 Impact factor: 10.864
Authors: Valentina Buda; Andreea Prelipcean; Carmen Cristescu; Alexandru Roja; Olivia Dalleur; Minodora Andor; Corina Danciu; Adriana Ledeti; Cristina Adriana Dehelean; Octavian Cretu Journal: Int J Environ Res Public Health Date: 2021-07-01 Impact factor: 3.390